Patient characteristics
| Characteristic . | All patients . |
|---|---|
| No. of patients | 48 |
| Disease type, n (%) | |
| DLBCL* | 28 (58) |
| Not otherwise specified | 18 (37) |
| Transformed from indolent | 10 (21) |
| HGBL-DH/TH | 8 (17) |
| Other aggressive† | 5 (11) |
| Mantle cell lymphoma‡ | 6 (12) |
| Follicular lymphoma | 1 (2)§ |
| Age | |
| Median (interquartile range), y | 58.5 (52-63) |
| ≥65 y, n (%) | 8 (17) |
| Male sex, n (%) | 35 (73) |
| ECOG performance status score ≥1, n (%) | 20 (42) |
| LDH, pre-lymphodepletion above the ULN, n (%) | 32 (67) |
| Disease stage, n (%) | |
| I or II | 1 (2) |
| III or IV | 47 (98) |
| Extranodal disease, n (%) | |
| Yes | 43 (90) |
| No | 5 (10) |
| IPI score, n (%)|| | |
| 0 or 1 | 7 (15) |
| 2 | 16 (33) |
| 3 or 4 | 25 (52) |
| Bulky disease (≥10 cm)¶ | |
| Yes | 8 (17) |
| No | 40 (83) |
| Tumor cross-sectional area# | |
| Median (interquartile range), mm2 | 3926 (2127-6769) |
| Previous therapies | |
| Median (interquartile range) | 4 (3-5) |
| Range | 1-11 |
| Four or more previous lines of therapy, n (%) | 34 (71) |
| Previous autologous HCT, n (%) | |
| Yes | 19 (40) |
| No | 29 (60) |
| Previous allogeneic HCT, n (%) | |
| Yes | 7 (15) |
| No | 41 (85) |
| Bridging therapy between leukapheresis and lymphodepletion, n (%) | |
| Intensive chemotherapy** | 7 (15) |
| High-dose corticosteroid†† | 9 (19) |
| Other‡‡ | 2 (4) |
| Any therapy between leukapheresis and lymphodepletion | 12 (25) |
| Characteristic . | All patients . |
|---|---|
| No. of patients | 48 |
| Disease type, n (%) | |
| DLBCL* | 28 (58) |
| Not otherwise specified | 18 (37) |
| Transformed from indolent | 10 (21) |
| HGBL-DH/TH | 8 (17) |
| Other aggressive† | 5 (11) |
| Mantle cell lymphoma‡ | 6 (12) |
| Follicular lymphoma | 1 (2)§ |
| Age | |
| Median (interquartile range), y | 58.5 (52-63) |
| ≥65 y, n (%) | 8 (17) |
| Male sex, n (%) | 35 (73) |
| ECOG performance status score ≥1, n (%) | 20 (42) |
| LDH, pre-lymphodepletion above the ULN, n (%) | 32 (67) |
| Disease stage, n (%) | |
| I or II | 1 (2) |
| III or IV | 47 (98) |
| Extranodal disease, n (%) | |
| Yes | 43 (90) |
| No | 5 (10) |
| IPI score, n (%)|| | |
| 0 or 1 | 7 (15) |
| 2 | 16 (33) |
| 3 or 4 | 25 (52) |
| Bulky disease (≥10 cm)¶ | |
| Yes | 8 (17) |
| No | 40 (83) |
| Tumor cross-sectional area# | |
| Median (interquartile range), mm2 | 3926 (2127-6769) |
| Previous therapies | |
| Median (interquartile range) | 4 (3-5) |
| Range | 1-11 |
| Four or more previous lines of therapy, n (%) | 34 (71) |
| Previous autologous HCT, n (%) | |
| Yes | 19 (40) |
| No | 29 (60) |
| Previous allogeneic HCT, n (%) | |
| Yes | 7 (15) |
| No | 41 (85) |
| Bridging therapy between leukapheresis and lymphodepletion, n (%) | |
| Intensive chemotherapy** | 7 (15) |
| High-dose corticosteroid†† | 9 (19) |
| Other‡‡ | 2 (4) |
| Any therapy between leukapheresis and lymphodepletion | 12 (25) |
ECOG, Eastern Cooperative Oncology Group; HGBL-DH/TH, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; ULN, upper limit of normal.
MYC rearrangement not available for 8 patients.
Two patients with Burkitt lymphoma, 1 with T-cell/histiocyte-rich large B-cell lymphoma, 1 with primary cutaneous diffuse large B-cell lymphoma/leg type, and 1 with high-grade B-cell lymphoma/not otherwise specified.
Pleomorphic morphology and/or Ki-67 >30%.
Patient with grade 3B follicular lymphoma per 2017 World Health Organization Classification.35
Scores on the IPI include low risk (0 or 1 point), low to intermediate risk (2 points), high to intermediate risk (3 points), and high risk (4 or 5 points).
Maximum tumor diameter ≥10 cm.36
Sum of the product of the perpendicular diameters of up to 6 target measurable nodes and extranodal sites.11
Intensive chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or equivalent).
More than one dose of dexamethasone 20 mg or equivalent not as part of a chemotherapy regimen.
Monoclonal antibody, immunomodulatory, and/or targeted small molecule drugs.